NTRK1 and neoplasm: Then, we selected 16 GC patients overexpressing NTRK1–3, defined as a ≥2.0-fold change (Table 1 and Figure 1) [16]; the incidence was 47%, which was much higher than the rate reported in previous studies on 17–33 different tumor types (2.2–14.2%) [3,17].